The mechanism was investigated in mice lacking PAD4 to find a decline in NETs, increased recruitment of CD8+ T cells, and lower tumor size when administrated with a programmed cell death protein 1 (PD‐1) blocker.88 Here, PDCD1 is linked to neoplasm.